Compare Jabil Inc (JBL) vs Merck & Co., Inc. (MRK) Price & Performance

Jabil IncTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Jabil Inc vs Merck & Co., Inc. — how do they compare? Jabil Inc trades at $360.5 (market cap $37.37B), while Merck & Co., Inc. trades at $130.36 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 8.6× Jabil Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

	JBL	MRK
Market Cap	$37.37B	$321.77B
Sector	Technology	Health
52-Week High	$385.50	$131.84
52-Week Low	$192.49	$77.60
Enterprise Value	$39.90B	$368.53B
Dividend Yield	0.09%	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Jabil Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

JBL

UBS upgrades Jabil, citing AI, healthcare, and automation growth with a $430 price target.Proactive Investors · 19 hours agoBullish Jabil expands into full data center services, targeting $40B revenue and $13.6B AI revenue by 2026.Seeking Alpha · 1 day agoBullish View details →

MRK

Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 4 hours agoBullish Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 22 hours agoBearish View details →

About Jabil Inc

Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.